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Herein, we evaluate the potential of using a simple solvent granulation process to prepare a binary drug
amorphous solid dispersion (ASD) containing two anti-HIV drugs, ritonavir and lopinavir. The drugs were
granulated onto a mixture of lactose and microcrystalline cellulose, followed by drying to remove the solvent.
The resultant granules were characterized and each drug was found to be X-ray amorphous. No crystallization
was observed following storage for 1 month under accelerated stability conditions (40 °C and 75% relative
humidity). The dissolution behavior of the compacted granules was compared with the marketed formulation.
The dissolution rate of ritonavir was found to be signiﬁcantly retarded relative to the commercial product when
the two drugs were co-granulated. However, comparable release could be achieved when each drug was individually granulated, followed by combination and compaction. The solvent granulation approach may be a
viable method to make ASDs of low dose drugs with low crystallization tendencies.

1. Introduction
With an increase in the number of therapeutically active compounds
exhibiting low water solubility, formulation strategies such as amorphization, salt formation, complexation, micellization, are increasingly
employed to improve solubility and bioavailability (Aisha et al., 2012;
Frank et al., 2012a; Loftsson, 2017; Takano et al., 2010). Among these,
amorphous formulations, which typically yield a higher solubility (supersaturated solution) and dissolution rate as compared to the crystalline state are often a preferred strategy (Hancock and Zograﬁ, 1997).
Other approaches such as complexation or micellar solubilization can
increase the drug concentration in solution but do not necessarily result
in supersaturation and thus will not improve the ﬂux across a biological
membrane (Frank et al., 2012b; Raina et al., 2015); ﬂux has been shown
to depend on the supersaturation gradient across the membrane rather
than the concentration diﬀerence (Borbás et al., 2016). Since amorphous drugs tend to transform to the more stable crystalline phase upon
storage, appropriate polymers are usually added to form a molecular
dispersion, thereby decreasing the molecular mobility of the system,
increasing the glass transition temperature (Tg), and providing kinetic
stabilization against crystallization (Kothari et al., 2015; Prasad et al.,
2014).
While there have been many investigations of amorphous solid

dispersions (ASD) containing a single drug, an emerging scenario is the
formulation of co-amorphous dosage forms. For these systems, there is a
need to understand the impact of having more than one drug in the
formulation. Multidrug formulations are becoming increasingly prevalent for diseases such as human immunodeﬁciency and hepatitis C
viral infections, whereby treatment regimens require the administration
of multiple drugs. These formulations either take advantage of a synergistic eﬀect of the two drugs (Zhang et al., 2000) or improve the
absorption of one drug by including another compound that interacts
with and inhibits the eﬄux transporters or to inhibit metabolic enzymes
(Drewe et al., 1999). Even though a multiple drug regimen can be
achieved by simultaneous administration of separately formulated
drugs, it may be preferable to co-formulate two or more drugs as ﬁxed
dose combinations (FDC) to improve patient compliance. A number of
such FDC dosage forms are marketed including Kaletra® (lopinavir/ritonavir), Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) and Harvoni® (sofosbuvir/ledipasvir). Some of these FDC products
contain drugs that are crystalline in nature (e.g. Coartem®) while others
have drugs that are formulated as amorphous solids to take advantage
of their improved bioavailability, for example lopinavir and ritonavir.
Recently, attention has been directed towards drug-drug co-amorphous
systems wherein many combinations have been found to give a dissolution and physical stability advantage over the individually
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3. Methods

formulated compounds. One example is naproxen which, though generally resistant to amorphization, could be made amorphous by mixing
with indomethacin (a drug in the same therapeutic class) (Löbmann
et al., 2011). Improved stability of the co-amorphous system can be due
to the formation of favorable intermolecular interactions between the
two drugs thereby resulting in a higher than expected Tg (Martinez
et al., 2016). Alternatively, it may be due to interference of the nucleation process as inferred in the case of nimodipine:nifedipine coamorphous blends wherein the Tg of the mixture was lower than expected but the system was nevertheless more resistant to crystallization
(Knapik-Kowalczuk et al., 2018). However, in terms of dissolution assessment, in many cases, comparisons are made between the co-amorphous system and the corresponding crystalline forms (Dengale et al.,
2014; Shayanfar and Jouyban, 2013; Tantishaiyakul et al., 2009). Occasions wherein the dissolution performance is improved relative to
that of the pure amorphous drug are usually seen in cases where the
amorphous co-former is acidic and the drug is a base, hence salt formation occurs, or the acidic component increases the solubility of the
drug by modifying the micro-environmental pH of the solute–solvent
interface (Fung et al., 2018). In other instances, the individual amorphous drug crystallized faster when compared to the co-amorphous
mixture and thus the dissolution advantage can be attributed to kinetic
factors (Allesø et al., 2009). However, it has been shown previously
that, when two drugs are miscible and uncharged, the amorphous solubility of each component in the mixture is invariably lower than that
of the pure individual amorphous components due to a decrease in their
chemical potential resulting from molecular level mixing (Alhalaweh
et al., 2016; Trasi and Taylor, 2015a, 2015b).
Amorphous intermediates are usually manufactured at commercial
scale using one of two main methods namely solvent evaporation (typically spray drying) or hot melt extrusion (HME) (Paudel et al., 2013;
Repka et al., 2008) whereby each process has both advantages and
limitations. HME requires that the drug is chemically stable at the high
processing temperature employed (typically greater than 120 °C) and
possesses a melt temperature that allows processing with a stabilizing
polymer. Spray drying requires organic solvents to dissolve both the
drug and the polymer leading to issues with controlling residual solvent
content, and high costs associated with solvent recycling. Another
drawback of spray drying is that the resultant powder may have a low
bulk density and can have high electrostatic charge which can make
powder handling diﬃcult (Murtomaa et al., 2004). Both of these approaches are cost intensive in the manufacturing sense with high capital
equipment costs. Since many drugs for the treatment of infectious diseases are used extensively in low-income countries, there is a need to
develop more economical formulations and manufacturing approaches
that can be performed in the developing countries.
In this study, we have evaluated the possibility of developing an
inexpensive manufacturing method to make amorphous solid dispersion formulations, wherein we studied the feasibility of formulating a
ﬁxed dose combination of lopinavir and ritonavir (Fig. 1) prepared
using wet granulation/solvent impregnation. Various techniques including X-ray powder diﬀraction, infrared spectroscopy and release
testing were used to characterize the resultant formulations.

3.1. Preparation of dispersions
Small scale experiments. An excipient mixture consisting of a 1:1 wt
blend of anhydrous lactose and MCC pH 101 was prepared by physical
mixing using a vortex mixer. A 1:1 DCM:MeOH solution containing one
or both of the drugs was then added to this mixture and granules were
formed by mixing using a spatula. The two drug components were initially used at the ratio present in the marketed formulations, i.e.
200 mg LPV:50 mg RTV. Other ratios of the drugs were also subsequently studied to improve mechanistic understanding. 200 mg of LPV,
50 mg RTV, and 250 mg of PVPVA were dissolved in 2–3 mL of 1:1
DCM:MeOH and added to 1.5 g of 1:1 MCC:anhydrous lactose and
mixed using a spatula. Formulations containing 5% w/w Span 20
(which is also present in the marketed formulation), or 0.1% w/w
Tween 80 were also prepared whereby the overall tablet weight was
maintained at 2 g. The granules were dried overnight in a vacuum oven,
followed by milling for 10 s in a cryogenic mill (6750 freezer mill, Spex
Sampleprep, Metuchen, NJ) to form a powder. RTV and LPV wet
granulated dispersions were also prepared by making granules containing just one drug (1:1 drug:polymer ratio) using the following formula, 50 mg RTV + 50 mg PVPVA + 400 mg excipients and 200 mg
LPV + 200 mg PVPVA + 1000 mg excipients. Preparation of the 20:80
drug:PVPVA dispersion was performed using a larger amount of excipient (3 g per tablet) as the base powder resulting in a total tablet
weight of above 4 g. A summary of all formulations is provided in Table
S1.
The resultant ASD formulation was placed in a desiccator with a
saturated solution of sodium chloride which provides a relative humidity of 75%. The container was placed at 40 °C and samples were
removed every 7 days and analyzed by XRPD to monitor crystallization.
Bench-top granulation. Bench-top granulation experiments were also
performed to verify that granules could be produced using more industrial-like processing equipment. A custom-made bench-top granulator, described in detail previously, was used (Wikstrom et al., 2008).
An excipient mixture consisting of 1:1 by weight blend of anhydrous
lactose and MCC pH 101 was prepared using a V – blender. Sixty grams
of this blend was placed in the granulator. A 1:1 DCM:MeOH solution
containing both of the drugs (12 g LPV and 3 g RTV) and PVPVA (15 g)
was then gradually added to the excipient blend using a peristaltic
pump. The rate of solvent addition was 25 mL/min, and addition occurred in < 4 min. The tip speed used was 94 m/sec. The solution was
added until complete granulation of the powder occurred. The granules
were sieved and dried overnight in a vacuum oven. The granules were
subsequently assayed for their drug content conﬁrming that a 10% drug
loading was achieved. The granules were then characterized in terms of
their Carr’s Index, Hausner ratio, angle of repose, and particle size
(using sieve analysis). Tablets containing 150 mg of granules were
prepared using a computer-controlled tablet press (Gamlen Tableting Ltd., Nottingham, UK) by direct compression. The granules were
compacted with a target load of 500 kg at the speed of 120 mm/min
using a 6 mm punch. The force-displacement data obtained during tablet preparation was analyzed to obtain the maximum load applied to
the tablet during the compression, detachment and ejection steps. The
tablets were evaluated for their hardness (Vanderkamp-Benchsaver
Series, Cary, NC) and friability (Vankel Friabilator, Cary, NC). Both the
tests were performed as per the speciﬁcations in USP.

2. Materials
Lopinavir and ritonavir were obtained from ChemShuttle (Hayward,
CA). Microcrystalline cellulose pH 101 (MCC) and anhydrous lactose
were obtained from Sigma-Aldrich (St. Louis, MO). Dichloromethane
(DCM) and methanol (MeOH) were obtained from Fisher Scientiﬁc
(Pittsburgh, PA). Cros-carmellose sodium was sourced from FMC
Biopolymer (Newark, DE). AluviaTM (Manufactured by Abbott GmbH &
Co, Ludwigshafen, Germany) was obtained from an Indian pharmaceutical distributor.

3.2. X-ray powder diﬀraction (XRPD)
The X-ray diﬀraction proﬁles of the powders were determined using
a Rigaku SmartlabTM diﬀractometer (Rigaku Americas, Texas, USA)
with a Cu-Kα radiation source and a D/tex ultra detector. Samples were
loaded onto glass sample holders and powder patterns were obtained
from 5 to 35° 2θ at a scan speed of 10°/min and a step size of 0.02°. The
2
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Lopinavir

Ritonavir

Fig. 1. Molecular structures of ritonavir and lopinavir.

voltage and current used were 40 kV and 44 mA respectively.

3.4. High performance liquid chromatographic (HPLC) analysis
HPLC analysis was performed using an Agilent HPLC 1260 Inﬁnity II
system (Agilent Technologies, Santa Clara, CA) equipped with a diode
array detector. The column used for analyzing the samples was a
SunﬁreTM C-18 analytical column (3.0 mm × 150 mm, 3.5 µm, 100 Å)
(Waters Corporation, Milford, MA). The mobile phase was an acetonitrile: water mixture at a ratio of 60:40 v/v and the ﬂow rate was
0.5 mL/min. The analysis was conducted at room temperature and the
detection wavelength was 215 nm. The retention times for RTV and LPV
were 3.9 and 4.5 min respectively. The concentration of the drug was
determined from the area under the curve of the drugs by comparing to
a standard curve prepared from a stock solution of the drugs, both of
which had R2 values of 0.999.

3.3. Dissolution testing
The dispersions prepared at small-scale containing 200 mg of LPV
and 50 mg of RTV were weighed and made into a compact using an E-Z
hydraulic press (International Crystal Laboratories, Garﬁeld, NJ) at 500
psi for 3 s before removing the pressure. Croscarmellose sodium (10 wt
%) was added to ensure tablet disintegration. Compacts were prepared
to improve wetting during dissolution testing as the powder had a
tendency to ﬂoat, and to provide a better comparison with the marketed
formulation. Tablets were added to 250 mL of pH 6.8 10 mM phosphate
buﬀer pH 6.8, maintained at 37 °C in a jacketed beaker and stirred with
a magnetic stirrer at 150 rpm. Samples were removed at regular time
intervals, ﬁltered through a 0.45um PTFE syringe ﬁlter (Tisch
Scientiﬁc, North Bend, OH) and analyzed by high performance liquid
chromatography (HPLC) as described below. The dissolution of
AluviaTM in pH 6.8 media was diﬃcult to determine due to signiﬁcant
diﬃculty in ﬁltering the dissolution medium. This was due to the formation of a milky solution during dissolution indicating the formation
of nanodroplets which clogged small pore size ﬁlters and passed
through ﬁlters with a larger pore size. Dissolution was also carried out
in 250 mL of 0.1 N HCl under the same conditions to mimic dissolution
in gastric media. For this medium, AluviaTM tablet dissolution also
could be determined. For the scaled-up granules, granules equivalent to
100 mg of drug content were added to a dissolution media consisting of
100 mL of 0.1 N HCl in a jacketed beaker maintained at 37 °C and
stirred with a magnetic stirrer at 150 rpm. Samples were removed at
regular time intervals and ﬁltered through a 0.45 μm PTFE syringe ﬁlter
(Tisch Scientiﬁc, North Bend, OH) and analyzed by HPLC.
A pH shift dissolution experiment was performed on the marketed
product by adding one tablet to 200 mL of 0.1 N HCl stirred at 150 rpm
and held at 37 °C. After 30 min, the solution was neutralized with
750 mg of NaOH (dissolved in 10 mL of water) and an additional 40 mL
of 100 mM pH 6.8 buﬀer was added and the dissolution was continued.
The amorphous solubility of the each drug in 10 mM pH 6.8 phosphate buﬀer was determined by preparing a stock solution of 20 mg/mL
of RTV or LPV in methanol and adding 100 µL of the solution to the
buﬀer containing 10 µg/mL HPMC (to inhibit crystallization) with
stirring at 37 °C. The solutions were then ultracentrifuged using an
Optima L-100 XP ultracentrifuge (Beckman Coulter Inc., CA, USA) with
a SW 41 Ti swinging bucket rotor attachment at 35,000 rpm at 37 °C.
The supernatant containing the molecularly dissolved drug was then
removed and analyzed using high performance liquid chromatography
(see below). The resultant concentration was taken as the amorphous
solubility.

3.5. Fourier transform Infra-red (FTIR) analysis
FTIR spectra of melt quenched RTV and LPV were obtained using a
Golden Gate ATR accessory (Specac, Fort Washington, PA) installed in a
Vertex 70 model IR Spectrophotometer (Bruker Optics, Billerica, MA).
A total of 64 scans were averaged in the spectral range of
400–4000 cm−1. The ATR unit, as well as the detector compartment,
were kept continuously ﬂushed with dry air. The spectra of the coamorphous systems were determined after mixing and melting 200 mg
LPV and 50 mg RTV into a pellet. This pellet was then exposed to the
0.1 N HCl dissolution media for 1 h and then dried. The surface of the
pellet that was exposed to the acidic media was scraped and the powder
analyzed to determine the change in drug ratio on the surface.
4. Results
4.1. XRPD analysis and stability testing
X-ray diﬀractograms of the 200/50 LPV/RTV granules prepared
with PVPVA showed an absence of crystalline peaks arising from either
drug suggesting that the drugs were present in their amorphous form.
Reference diﬀractograms of crystalline ritonavir, lopinavir, and a blend
of lactose and MCC are shown in Figure S1. The Bragg peaks seen in
Fig. 2, in the diﬀractograms of the granules, arise from lactose which is
in its crystalline form in the granules. In contrast, a physical mixture of
crystalline drugs and excipients at the same drug loadings yielded an
XRPD pattern with clearly distinguishable drug crystalline peaks, for
example there are several peaks appearing at values below 10° 2Θ that
are due the presence of crystalline drugs; these are absent in the
granules (Fig. 2). Storage of the granules under accelerated stability
open dish conditions (40 °C/75%RH) for one month did not result in the
appearance of any crystalline peaks indicating that the granules
3
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supersaturations (where relative supersaturation, S, is C/C* where C is
the experimentally measured concentration and C* is the crystal solubility) of ~17 and ~7 for RTV and LPV respectively. However, when
the 200/50 LPV/RTV granules containing a co-granulated intimate
mixture of the drugs were dissolved, the maximum concentrations of
each drug achieved were considerably lower, with the RTV concentration reaching a plateau at 4–5 µg/mL, while the LPV concentration reached around 15 µg/mL. Correspondingly, the supersaturation
ratio was reduced to a factor of only ~3 for RTV, while that of LPV was
reduced slightly to 5.
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4.2.2. Dissolution in 0.1 N HCl
RTV is a weakly basic drug with pKa values of 1.8 and 2.6 for the
two thiazole moieties. Therefore, it is highly, although not completely,
ionized at pH 1.2, resulting in increased solubility (Law et al., 2001). At
pH 1.2 the solubility of crystalline RTV is ~0.4 mg/mL (Law et al.,
2001) and for dissolution experiments at pH 1.2, sink conditions with
respect to crystalline solubility exist. Consequently, when the dissolution is performed in an acidic media, signiﬁcantly more RTV is molecularly dissolved relative to that in neutral media due to the higher
solubility of the ionized form. The molecularly dissolved RTV concentration upon AluviaTM dissolution reached around 170 µg/mL at the
end of 2 h while the LPV concentration remained close to its amorphous
solubility (Fig. 4). LPV is un-ionized at this pH and therefore does not
dissolve to a higher concentration relative to that observed in neutral
media. Interestingly, despite the acidic dissolution medium providing
sink conditions, the concentration of molecularly dissolved RTV at the
end of the dissolution experiment is lower than expected indicating
incomplete release; the expected ﬁnal solution concentration if all of
the RTV dissolved is 200 μg/mL. To determine the reason for this, a
200 µg/mL solution of RTV was prepared in 0.1 N by dissolving RTVonly granules and to this was added 0.8 mg/mL of LPV, prepared by
dissolving LPV-only granules, and the system was stirred for one hour.
The RTV free drug concentration after addition of LPV decreased by
10% to around 180 µg/mL, indicating that the presence of LPV induced
a small amount of RTV precipitation (data not shown).
The release rate and extent of RTV from the tableted granules
(where both RTV and LPV were co-granulated) was signiﬁcantly lower
than that from AluviaTM with the concentration being less than 100 µg/
mL after 2 h, while the LPV release rate and extent were comparable
(Fig. 3). The scaled-up co-granulated system likewise showed a lower
release proﬁle than observed from AluviaTM (Figure S3).

35

Degrees ( 20)

Fig. 2. XRPD proﬁles of the granules before and after storage at accelerated
storage conditions for 4 weeks shows that there is no development of crystalline
peaks characteristic of either drug, whereby peaks arising from each drug can
be clearly seen in the physical mixture.

prepared by solvent evaporation were resistant to crystallization for this
time period. When the drugs were granulated individually with a blend
of MCC and lactose, no crystallization was observed after storage under
similar conditions for one month (Figure S2).
4.2. Dissolution testing
4.2.1. Dissolution in pH 6.8 buﬀer
The dissolution of RTV and LPV granules formulated as a single
component and as a co-granulated formulation was evaluated in both
near-neutral and acidic media, focusing on the maximum extent of
supersaturation achieved. Under near-neutral pH conditions, the crystalline solubility of RTV is 1.8 µg/mL and that of LPV is 2.9 µg/mL,
hence the dissolution conditions are highly non-sink with respect to the
crystalline solubility. Neither compound is ionized at pH 6.8. Further,
the dissolution data represent the concentration of molecularly dissolved species whereby the samples have been ﬁltered to remove any
colloidal aggregates. The resultant values can be used to calculate the
extent of supersaturation, which is considered important for enhancing
the rate of membrane ﬂux in vivo (Bevernage et al., 2013). As can be
seen from Fig. 3, RTV granules dissolved to a maximum concentration
of just below 30 µg/mL, while LPV granules reached a ﬁnal concentration of around 20 µg/mL at the end of 2 h of dissolution when the
drugs were granulated and dissolved individually. These concentrations
are close to the amorphous solubility of these compounds in this
medium i.e. 31 µg/mL and 19 µg/mL for RTV and LPV respectively.
Thus the solutions are maximally supersaturated with relative

4.2.3. Eﬀect of pH shift on dissolution
When the marketed formulation was ﬁrst dissolved in acidic media
and the pH subsequently increased, we observed a rapid decrease in the
RTV concentration to below 5 µg/mL (Fig. 5), which cannot be accounted for by the modest dilution. The resultant level of supersaturation is similar to that observed for RTV released from the co-
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4.2.5. Eﬀect of LPV:RTV ratio on release
To better understand the reduced solution concentrations of RTV in
the presence of LPV (i.e. when both drugs are in the same ASD), we also
prepared and evaluated granules with diﬀering ratios of LPV and RTV,
Fig. 6. Change in the concentration of molecularly
dissolved drug when the pH is shifted from 1.2 to
6.8. Concentrations were determined following ultracentrifugation to remove any precipitates. The
inset shows the lack of birefringence of the observed
drug precipitates indicating that precipitated material is non-crystalline. The dilution factor was 25%.
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Various strategies were employed to improve the dissolution proﬁle
of the wet granulated dispersions, so that a better match to the commercial product was achieved in terms of the molecularly dissolved
drug concentrations in the stomach environment. First, the total drug
loading (relative to polymer) was reduced from 50 wt% to 20 wt%.
However, no overall improvement in release performance was achieved
using this approach (data not shown). Next, addition of surfactants was
evaluated; a surfactant is present in the commercial product and surfactants have been shown to improve release from amorphous formulations (Mosquera-Giraldo et al., 2018).
As shown in Fig. 7, the addition of surfactants in the dispersions did
not aid in improving the dissolution rate of RTV. The addition of Tween
resulted in a similar proﬁle to in the absence of the surfactant, while the
addition of Span 20, present in the marketed formulation, seemed to
reduce the rate and extent of RTV release. Neither surfactant had an
appreciable impact on LPV release.

::,
E 80
.......

0

•

the pH shift experiments shown in Fig. 5, and the single stage dissolution experiments on the co-granulated drugs shown in Fig. 3,
whereby the RTV concentration at higher pH is considerably lower than
the amorphous solubility of RTV alone.

100

u

•

Fig. 7. Dissolution of LPV-RTV granules at 1:1 drug:polymer ratio in 0.1 N HCl
in the presence of 0.1% Tween and 5% Span 20 in the formulation.

120

-

20

•

e LPV-Span

Time (mins)

granulated ASD under neutral conditions (Fig. 3). At ﬁrst glance, it
might be assumed that this rapid decrease upon pH shift is due to the
generation of an initially high supersaturation due to a decrease in the
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To better evaluate the crystallization tendency upon pH shift, this
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ratio of peaks at 1630 cm−1 and 1718 cm−1 increases from 7.7 to 11.2,
indicating a preferential loss of RTV from the surface during dissolution. In general, the spectrum becomes slightly more LPV-like after
partial dissolution with additional subtle changes in the peaks, as
shown by the arrows in Fig. 9. Given that the ATR sampling methodology is somewhat surface sensitive (Planinsek et al., 2006), these
observations are consistent with surface enrichment of LPV due to
preferential dissolution of RTV. This is also consistent based on mass
balance considerations using the dissolution data under acidic conditions where it is apparent that relatively more RTV dissolves than LPV.
Consequently, the amount of LPV in the undissolved ASD increases
relative to the amount of RTV.
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Fig. 8. Dissolution of 50 mg RTV in 250 mL 0.1 N HCl for dispersions containing diﬀering ratios of LPV and RTV.

4.4. Properties of granules and tablets
The properties of granules produced using the bench-top granulator,
and tablets prepared from these granules, were evaluated. The angle of
repose value of granules was found to be 36.2 ± 0.7°. The Carr’s Index
and Hausner ratio values were 14.4 ± 3.5% and 1.17 ± 0.05 respectively. Sieve analysis of granules indicated that more than 80% of
the particles lie in the size range of 150–595 µm (Figure S4). The
granules contained less than 1.5% of ﬁnes (particle size < 45 µm). The
calculated span value of granules was 1.72. The drug load % was found
to be 8.4% for LPV and 2% for RTV. For tablet preparation, the maximum loads applied during compression, detachment and ejection steps
were 518.7 ± 0.7 kg, 19.1 ± 3.1 kg, and 87.6 ± 4.4 kg respectively.
All tablets were found to be intact after the friability test, with a friability of 0.7%. The hardness of the tablets was 10.17 ± 0.53 kPa. These
results indicate that this manufacturing approach leads to granules with
acceptable ﬂow properties that can be compressed into tablets of low
friability and suﬃcient hardness.

namely 125:125 and 50:200 LPV:RTV, in addition to the marketed
200:50 ratio. The dissolution of tablets made from these granules in
0.1 N HCl, such that the amount of RTV added to the media was the
same in all the samples, showed that RTV reaches its highest concentration when it is prepared at the ratio 50:200 LPV:RTV (Fig. 8).
Thus, for a constant total amount of RTV, a lower ratio of LPV enables
enhanced RTV dissolution from the amorphous co-granulated mixture.
This observation conﬁrms that the presence of LPV, intimately mixed
with RTV as in the co-granulated ASDs retards RTV release.
4.2.6. Eﬀect of granulating the drugs separately
A diﬀerent approach employed to prepare the FDC tablets in an
eﬀort to improve the release proﬁles was to use individually granulated
powders. In other words, granules with only one drug in the dispersion
were prepared and then blended and compacted. Alternatively, bilayered tablets were prepared where the granules containing each drug
were kept physically separated. As can be seen from Fig. 9, both of these
approaches resulted in rapid RTV releases whereby the ﬁnal concentrations achieved were similar to those seen for the AluviaTM formulation.

5. Discussion
Wet granulation using organic solvents appears to be a possible
alternative approach to HME and spray drying for preparing an amorphous dosage form of the slowly crystallizing compounds, RTV and
LPV, albeit with certain caveats. Thus, the amorphous forms of the
drugs were successfully generated by solvent granulation/impregnation, and the resultant granules were found to be physically stable
against crystallization. Moreover, granules with good ﬂow and compression properties could be produced using this approach. However,
there are factors that need to be considered when drugs are formulated
and produced using this approach. One consideration is the ﬁnal size of
the tablet, since a relatively large excipient mass is required for successful granulation with the drug-polymer organic solvent solution to
avoid formation of a sticky mass. Clearly important factors here include
the dose of the drug, as well as the solubility of the drug and polymer in
the solvent system employed. Thus, the wet granulation approach is

4.3. FTIR analysis to understand dissolution behavior
The FTIR spectra of the two drugs are very similar (Fig. 10) with the
main diﬀerences observed in the carbonyl spectral region of
1575–1800 cm−1 where RTV has an additional peak at 1704 cm−1
adjacent to the overlapping peaks at around 1630 cm−1. RTV also has
two large peaks at 1229 and 878 cm−1 which are absent in LPV. When
the two drugs are mixed and melt quenched together at a ratio of
200:50 LPV:RTV, the peaks uniquely representative of RTV are hard to
distinguish, presenting, for example, as a small shoulder at 1718 cm−1.
Upon exposure to 0.1 N HCl and partial dissolution of the surface of the
amorphous mixture, the intensity of the shoulder decreases and the

(a)

-g

180
160
140

!

}120
i5 100
·;:,
80
~C:
60
Cl/
u
C:
40
0
u
20
0

(b)

!

•

• •

200
180
160
140
120
100
80
60
40
20
0

!

• Avg RTV
• Avg LPV

•

• • • •
0

50

•
100

150

f

!

•

!

• Avg RTV
• Avg LPV

•

•

• • • •
0

•

•

50

100

150

Time (min)

Time (min)

Fig. 9. Dissolution from (200:50 LPV:RTV) tablets prepared by (a) mixing individually granulated RTV and LPV and then compressing into one tablet and (b)
compressing the individually granulated powders separately as bi-layered tablets. Dissolution medium is 0.1 N HCl.
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Fig. 10. FTIR spectra of (a) pure amorphous RTV, (b) pure amorphous LPV, (c) 200:50 LPV:RTV melt quenched amorphous blend and (d) 200:50 LPV:RTV melt
quenched amorphous blend after exposure to 0.1 N HCl for 1 h.

likely to be best suited for low dose formulations, or those where the
drug and polymer are highly soluble in the solvent system, allowing a
lower volume of solvent to be used. This issue also can be potentially, at
least partially, mitigated by using excipients with a higher solvent adsorption capacity; preliminary experiments showed that using a higher
amount of MCC enabled an increase in drug loading. Alternatively,
ﬂuid-bed granulation is also a possible alternative, where a larger volume of solvent is less of an issue due to rapid solvent evaporation,
facilitating a decrease in the amount of excipients. Of course, the drug
also must be resistant to crystallization during the solvent evaporation
process. Hence, more slowly crystallizing compounds, such as those
with higher molecular weights and more complex structures, are most
suitable for this general approach. Additionally, adequate drying is
required to remove the organic solvent used to dissolve the hydrophobic drugs. The use of organic solvents to dissolve the drug and mix
with the polymer in a simple manufacturing process is not without
precedent. Tacrolimus amorphous solid dispersions (the commercial
product is Prograf®) are prepared by dissolution of the drug in an organic solvent, solvent impregnation into the polymer, solvent removal,
and then blending with additional excipients prior to ﬁlling into capsules (Honbo et al., 1987; Trasi et al., 2017; Yamashita et al., 2003).
The wet granulation approach described herein is attractive since it can
potentially reduce the number of required processing operations, producing granules that can be mixed with a disintegrant and then compressed.
In terms of dissolution performance, the co-granulated sample in the
neutral media resulted in lower concentrations of both drugs relative to
dissolution of single component granules (when dissolved alone),
whereby the concentration of RTV was depressed more than that of LPV
(Fig. 3). The reason for the lowered concentration upon dissolution of
the co-granules is due to the mixing of the two compounds in the
amorphous solid state, i.e. formation of a co-amorphous system. This
results in a mutually decreased chemical potential, and thus a lowered
amorphous solubility of each compound, which also decreases the
driving force for dissolution, as described in detail previously (Trasi and
Taylor, 2015b). In other words, mixing the drugs together to form a
single phase amorphous system, is detrimental to the amorphous solubility of each drug. Further, RTV is aﬀected to a greater extent than
LPV. This is because the extent of the amorphous solubility reduction
caused by mixing with a second compound in the amorphous phase is
dependent on the relative proportions of each compound, with the
minor component experiencing a greater extent of amorphous solubility
reduction than the major component. Because RTV it is present in a
lower amount in the co-granulate (the ratio of LPV:RTV is 4:1), it experiences a greater decrease in chemical potential, consistent with a
greater extent of dilution in the co-amorphous system brought about by
mixing with the larger amount of LPV. In other words, molecular

mixing of both components into a single amorphous phase negatively
impacts their dissolution performance (Alhalaweh et al., 2016; Trasi
and Taylor, 2015b), explaining the data presented in Fig. 3.
While the mutually reduced amorphous solubility explains the
single step, pH 6.8 dissolution results (Fig. 3), the situation is much
more complex for two-step dissolution, whereby the pH is initially
acidic, and then increased to pH 6.8. This is because one of the components, RTV, can undergo ionization at low pH. Due to the higher
solubility of the ionized form, RTV releases from the granules to a much
higher concentration in acid relative to at neutral conditions. However,
when the pH increases, RTV solubility decreases due to the change in
ionization state, with the solution becoming supersaturated. Further, if
the un-ionized concentration exceeds the amorphous solubility, as in
this study, liquid liquid phase separation with the formation of amorphous nanodroplets occurs (Ilevbare and Taylor, 2013; Sugihara and
Taylor, 2018). Given that both RTV and LPV are present in the solution
phase following pH change, mixing of the neutral drug species occurs.
Mixing between RTV and LPV in the nanodroplets will result in the
same amorphous solubility (and hence concentration) suppression
phenomenon described above. This can be clearly seen with the pH
switching experiments shown in Figs. 5–6, where only the molecularly
dissolved drug was measured (the precipitated material was removed
by centrifugation). Under acidic conditions, high RTV concentrations
are achieved upon dissolution due to ionization, while after the pH
increase, the molecularly dissolved RTV concentration (i.e. the extent of
supersaturation) plummets. This decrease can be attributed to three
factors, 1) a modest dilution factor (25%), 2) a change in ionization
state which leads to the amorphous solubility being exceeded, and
hence the formation of a drug-rich phase with the loss of free drug from
solution and, 3) suppression of RTV amorphous solubility by mixing of
RTV and LPV in the nanodroplets.
When the drug release proﬁles of the co-granulated sample and
AluviaTM are compared in acidic media, it can be seen that the release
of RTV is lower from the granules relative to the commercial tablets. It
is desirable that the release behavior of the drugs prepared using wet
granulation matches that of the innovator product, therefore it is of
interest to understand potential causes for the diﬀerences. Most likely
diﬀerences in drug:polymer ratios play a part in these observations,
combined with the solubility suppression phenomenon in the coamorphous mixtures. Drug release from an ASD typically falls within
one of two regimens namely, drug-controlled or polymer-controlled.
When the polymer is hydrophilic (such as PVPVA), polymer-controlled
release will result in rapid drug dissolution. On the other hand, in a
drug-controlled regime, slow drug dissolution would result for a hydrophobic drug. Whether the dissolution is drug-controlled or polymercontrolled depends on the drug-polymer ratio. The drug dissolution
behavior of AluviaTM appears to be polymer-controlled since at pH 6.8,
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component) and lopinavir (major component) using this approach, we
found that the presence of lopinavir in the co-amorphous system depressed the release of ritonavir. This issue could be largely resolved by
preparing individual ASD granules of each drugs, followed by mixing
and compaction. Clearly the phase behavior of ﬁxed dose combinations
of amorphous formulations is highly complex and needs to be considered when designing the formulation.
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Fig. 11. Proposed mechanism for retardation of RTV dissolution from coamorphous system with LPV. Dissolution of RTV from the surface of the particles in acidic media leaves behind a LPV-rich surface which acts as a barrier
for the remaining RTV to dissolve.
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a milky solution was formed consistent with drug dissolution to above
the amorphous solubility of each component, followed by liquid liquid
phase separation and nanodroplet formation. Since nanodroplet formation during dissolution of ASDs is normally seen in the case of low
drug loading (Purohit and Taylor, 2017), and speciﬁcally for RTVPVPVA ASDs it has been shown to occur only for dispersions with a
drug loading less than 25% (Indulkar et al., 2019), it is likely that the
total drug loading in the marketed formulation is in this range or lower.
In the wet granulated powders prepared herein, a higher drug loading
dispersion was prepared (50%) to try and keep the ﬁnal tablet weight at
a reasonable value. In this regimen, we expect the drug release to be
drug-controlled rather than polymer-controlled, based on previous observations with RTV and PVPVA dispersions (Indulkar et al., 2019). If
only amorphous RTV was present in the ASD, then the drug release
would have been fast and complete, since the drug ionizes upon contact
with the medium and has a high driving force for dissolution. However,
when present in combination with LPV, we expect the polymer to initially release faster than the drugs, leading to drug enrichment
(Indulkar et al., 2019). Further, RTV will be preferentially released
relative to LPV due to its higher solubility, thus the surface will become
enriched with LPV after the initial release of RTV. At this point, the
release will be mainly controlled by LPV, which is less soluble in acidic
media since it does not ionize. This pattern of events is supported by
evaluation of dispersions with high proportions of RTV, where a greater
extent of RTV release is observed (Fig. 7). Further, a simple mass balance consideration supports the contention that LPV becomes enriched
on the surface of the co-amorphous system after partial dissolution in
acidic media. The remaining RTV now has to diﬀuse through a barrier
layer that is LPV-rich, hindering complete dissolution. This proposed
mechanism is shown in Fig. 11.
Since the presence of LPV intimately mixed with RTV resulted in
retarded RTV release, even under favorable release conditions, i.e. in an
acidic medium, the best approach appears to be of granulating the two
drug separately and then either adding disintegrant and mixing prior to
compaction or to make bi-layered tablets to physically separate the
drugs. This approach led to much improved dissolution proﬁles, as
shown in Fig. 8. Clearly this approach enables each drug to dissolve
independently and better exploits the ionization of RTV in the acidic
medium.
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